Company news
Inoviq Ltd (ASX:IIQ) news
Inoviq Ltd news releases on 6ix. Latest, Jun 29, 2021: BARD1 Autoantibody Test Results for Ovarian Cancer Published
Press releases — page 3
BARD1 Autoantibody Test Results for Ovarian Cancer Published
June 28, 2021
Update on Legal Proceedings
June 4, 2021
BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test
May 24, 2021
BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference
May 18, 2021
BARD1 Launches its RUO EXO-NET Product
May 17, 2021
Appendix 4C and Quarterly Activities Report
April 30, 2021
Positive Results from the BARD1 Autoantibody Assay
April 28, 2021
BARD1 Signs Option Agreement for Type 3C Diabetes Test
April 12, 2021
Positive Results Evaluation of EXO-NET in Pancreatic Cancer
March 15, 2021
Appendix 4D and Half-year financial report
February 26, 2021
Commencement of Legal Proceedings Against BARD1
February 23, 2021
Excellent SubB2M Breast Cancer Test Data
February 14, 2021
Outstanding SubB2M Ovarian Cancer Test Data
February 10, 2021
AGM & CEO Presentations and Chairmans Transcript
November 26, 2020
BARD1 Gains New High-volume Customer for its hTERT Test
November 22, 2020
Successful BARD1 Kit Evaluation
September 22, 2020
BARD1 Awarded BTB Funding to Develop Breast Cancer Test
September 2, 2020
Appendix 4E and Annual Report to Shareholders
August 24, 2020
European Patent Validated
August 10, 2020
Quarterly Business Update & Appendix 4C
July 29, 2020
BARD1 COMPLETES SIENNA ACQUISITION
July 28, 2020
Quarterly Activities Report & Appendix 4C
April 28, 2020
BARD1 Signs Contract with Griffith University
April 1, 2020
Half Yearly Report and Accounts
February 25, 2020
Appendix 4C Quarterly Cashflow Report
January 29, 2020
Appendix 4C - quarterly
October 29, 2019
Phase 3 Assay Development Milestone Reached
October 7, 2019
Quarterly Business Update and Appendix 4C
July 30, 2019
Completion of Capital Raising Package
July 11, 2019
Closure of Entitlement Offer and Shortfall Notification
July 9, 2019
Progress on Assay Development Program
July 1, 2019
Offer Document
June 18, 2019
Capital Raising and Board Changes
June 17, 2019
EUROPEAN PATENT VALIDATED
June 2, 2019
R&D Tax Incentive Refund
May 27, 2019
U.S. Patent Issued
April 30, 2019
Response to ASX Price and Volume Query
April 1, 2019
Cancer Vaccine Study Results
February 14, 2019
Closure of Entitlement Offer and Shortfall
December 12, 2018
Rights Offer Document
November 18, 2018
Capital Raising Indicative Timetable
November 12, 2018
Non-Renounceable Issue
November 8, 2018
Pause In Trading
November 7, 2018
Quarterly Activities Report and Cashflow
October 30, 2018
Grant of Additional Chinese Patent Core BARD1 Patent Family
October 24, 2018
Development of world first BARD1 Breast Cancer Test
October 23, 2018
Bard1 Ovarian Test Results
September 6, 2018
Appendix 4E
August 31, 2018
Quarterly Activities Report and Appendix 4C
July 31, 2018
US Patent Issued Protecting BARD1 Ovarian Test
July 11, 2018